The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
|Videos|July 7, 2017
Dr. Huffman on Survival Analysis of Patients With Pseudopapillary Tumors of the Pancreas
Author(s)Brandon Huffman, MD
Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.
Advertisement
Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.
Solid pseudopapillary tumors make up only 2% of all pancreatic tumors. Using the National Cancer Database, the outcomes of patients with solid pseudopapillary tumors were collected and evaluated.
Advertisement
Related to this article
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5